Literature DB >> 9805028

Unconventional therapies for cancer: a refuge from the rules of evidence?

I F Tannock, D G Warr.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9805028      PMCID： PMC1232739     

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  10 in total

Review 1.  Unconventional therapies for cancer: 5. Vitamins A, C and E. The Task Force on Alternative Therapies of the Canadian Breast Cancer Research Initiative.

Authors:  E Kaegi
Journal:  CMAJ       Date:  1998-06-02       Impact factor: 8.262

Review 2.  Unconventional therapies for cancer: 6. 714-X. Task Force on Alternative Therapeutic of the Canadian Breast Cancer Research Initiative.

Authors:  E Kaegi
Journal:  CMAJ       Date:  1998-06-16       Impact factor: 8.262

Review 3.  Unconventional therapies for cancer: 2. Green tea. The Task Force on Alternative Therapies of the Canadian Breast Cancer Research Initiative.

Authors:  E Kaegi
Journal:  CMAJ       Date:  1998-04-21       Impact factor: 8.262

Review 4.  Unconventional therapies for cancer: 3. Iscador. Task Force on Alternative Therapies of the Canadian Breast Cancer Research Initiative.

Authors:  E Kaegi
Journal:  CMAJ       Date:  1998-05-05       Impact factor: 8.262

5.  Why patients use alternative medicine: results of a national study.

Authors:  J A Astin
Journal:  JAMA       Date:  1998-05-20       Impact factor: 56.272

6.  Randomized placebo-controlled evaluation of hydrazine sulfate in patients with advanced colorectal cancer.

Authors:  C L Loprinzi; S A Kuross; J R O'Fallon; D H Gesme; J B Gerstner; R M Rospond; C D Cobau; R M Goldberg
Journal:  J Clin Oncol       Date:  1994-06       Impact factor: 44.544

7.  Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer.

Authors:  C L Loprinzi; R M Goldberg; J Q Su; J A Mailliard; S A Kuross; A W Maksymiuk; J W Kugler; J R Jett; C Ghosh; D M Pfeifle
Journal:  J Clin Oncol       Date:  1994-06       Impact factor: 44.544

8.  Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial.

Authors:  E T Creagan; C G Moertel; J R O'Fallon; A J Schutt; M J O'Connell; J Rubin; S Frytak
Journal:  N Engl J Med       Date:  1979-09-27       Impact factor: 91.245

9.  High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison.

Authors:  C G Moertel; T R Fleming; E T Creagan; J Rubin; M J O'Connell; M M Ames
Journal:  N Engl J Med       Date:  1985-01-17       Impact factor: 91.245

10.  A clinical trial of amygdalin (Laetrile) in the treatment of human cancer.

Authors:  C G Moertel; T R Fleming; J Rubin; L K Kvols; G Sarna; R Koch; V E Currie; C W Young; S E Jones; J P Davignon
Journal:  N Engl J Med       Date:  1982-01-28       Impact factor: 91.245
  10 in total
  2 in total

1.  Proof versus plausibility: rules of engagement for the struggle to evaluate alternative cancer therapies.

Authors:  L J Hoffer
Journal:  CMAJ       Date:  2001-02-06       Impact factor: 8.262

2.  Discussing complementary therapies: there's more than efficacy to consider.

Authors:  T Truant; M McKenzie
Journal:  CMAJ       Date:  1999-02-09       Impact factor: 8.262
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.